Since NF-κB pathway plays a pivotal role in MM biology, there has been a persistent attempt to target NF-κB signaling and its effectors in anti-myeloma therapy, such as monoclonal antibodies against BAFF and BCMA, and small molecule inhibitors against NIK and IKK, among others [32]. Here, TNFRSF17 is linked to Miyoshi myopathy.